Stay updated on Sitravatinib and Nivolumab in Kidney Cancer Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib and Nivolumab in Kidney Cancer Clinical Trial page.

Latest updates to the Sitravatinib and Nivolumab in Kidney Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page displays the study record for the completed sitravatinib and nivolumab kidney cancer trial, including its eligibility criteria, study design, outcomes, and posted results.SummaryDifference55%

- Check15 days agoChange DetectedThe site footer revision changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA notice about NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” appears above the page’s 403 error.SummaryDifference1%

- Check29 days agoChange DetectedThe footer’s site revision label changed from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check36 days agoChange DetectedThe displayed site revision changed from v3.7.0 to v3.7.1 on the ClinicalTrials.gov error page.SummaryDifference0.2%

- Check50 days agoChange DetectedRemoved the 403 Forbidden markup and the Home label from the page’s HTML, affecting only the error/navigation elements rather than the visible study content. The core study details remain unchanged.SummaryDifference0.5%

Stay in the know with updates to Sitravatinib and Nivolumab in Kidney Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib and Nivolumab in Kidney Cancer Clinical Trial page.